 A TRIAL EVALUATING THE EFFICACY AND SAFETY OF ENDOTAG-1 IN COMBINATION WITH PACLITAXEL AND GEMCITABINE COMPARED WITH PACLITAXEL AND GEMCITABINE AS FIRST-LINE THERAPY IN PATIENTS WITH VISCERAL METASTATIC TRIPLE-NEGATIVE BREAST CANCER: 